|
Anemia
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Mutation analysis of COX4I2 is warranted in patients with malabsorption due to exocrine pancreatic insufficiency and in patients with dyserythropoeitic anemia.
|
19268275 |
2009 |
|
Exocrine pancreatic insufficiency
|
0.110 |
Biomarker
|
disease |
BEFREE |
Mutation analysis of COX4I2 is warranted in patients with malabsorption due to exocrine pancreatic insufficiency and in patients with dyserythropoeitic anemia.
|
19268275 |
2009 |
|
Hyperglycemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
STZ-induced hyperglycemia resulted in a decrease of muscle oxidative capacity and decreased PGC-1α and cytochrome c oxidase subunit 4 (COX-4) expression levels; while, application of transcutaneous CO2 attenuated this effect, and enhanced the expression levels of endothelial nitric oxide synthesis (eNOS).
|
31184310 |
2019 |
|
Myocardial Ischemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We sought to investigate the expression of this pathway along with the expression of mitochondrial biogenesis (PGC-1α [peroxisome proliferator-activated receptor-γ coactivator-1α]), dynamics (DRP-1 [dynamin-related protein 1], OPA-1 [optic atrophy 1], and MFN 2 [mitofusin 2]), and oxidative phosphorylation (citrate synthase and electron transport chain complexes) markers and COX IV (cytochrome C oxidase) activity in myocardium from patients with valvular or ischemic heart disease and heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
|
30744415 |
2019 |
|
Tumor Angiogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
COX4I2 and PLAT were highly correlated with blood supply in PCC which contribute to angiogenesis in PCC, which could be used as biomarkers to better indicate tumor angiogenesis, or targets to regress tumor angiogenesis as treatment.
|
31106414 |
2019 |
|
Heart failure with preserved ejection fraction [HFpEF]
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We sought to investigate the expression of this pathway along with the expression of mitochondrial biogenesis (PGC-1α [peroxisome proliferator-activated receptor-γ coactivator-1α]), dynamics (DRP-1 [dynamin-related protein 1], OPA-1 [optic atrophy 1], and MFN 2 [mitofusin 2]), and oxidative phosphorylation (citrate synthase and electron transport chain complexes) markers and COX IV (cytochrome C oxidase) activity in myocardium from patients with valvular or ischemic heart disease and heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
|
30744415 |
2019 |
|
Adrenal Gland Pheochromocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
COX4I2 was verified to be increased gradually with angiogenesis with increasing severity, and PLAT was shown to be decreased with angiogenesis in PCC, by quantitative reverse-transcription polymerase chain reaction and immunohistochemistry.
|
31106414 |
2019 |
|
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The tumor samples were pathohistologically (HE) and immunohistochemically (Ki-67, CD 31, COX IV, GLUT-1, iNOS) assessed and the main organs toxicologically analyzed, including the control animals that had received metformin and caffeine.
|
29762853 |
2018 |
|
Cardiomyopathy, Familial Idiopathic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In case of myocardial insufficiency and DCM, decreased expression of COX 4 results in an impaired CytOx activity.
|
30223867 |
2018 |
|
Cytochrome-c Oxidase Deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
The accumulation of H(2)S over time causes progressive COX deficiency in animal tissues and human cells, which is associated with reduced amount of COX holoenzyme, and of several COX subunits, including mitochondrially encoded cytochrome c oxidase 1 (MTCO1), MTCO2, COX4, and COX5A.
|
20812865 |
2011 |
|
Malabsorption Syndrome
|
0.010 |
Biomarker
|
group |
BEFREE |
Mutation analysis of COX4I2 is warranted in patients with malabsorption due to exocrine pancreatic insufficiency and in patients with dyserythropoeitic anemia.
|
19268275 |
2009 |
|
Myopathy
|
0.010 |
Biomarker
|
group |
BEFREE |
We evaluated at a single fiber level the expression of COX II (mtDNA-encoded) and COX IV (nuclear DNA-encoded) subunits in 12 HIV-infected patients with zidovudine myopathy.
|
10912924 |
2000 |